N/A
N=900
Uniformity of Oral Contrast Material in the Bowel
Known or Suspected Abdominal Disease
Bottom Line
View on ClinicalTrials.gov: NCT02542046 ↗Enrolled (actual)
900
Serious AEs
0.0%
Results posted
Nov 2019
Primary outcome: Primary: Number of Participants With Non-uniform Bowel Lumen Opacification at CT Imaging — 140; 73; 68 Participants
Study Design & Population
- Study type
- Observational
- Phase
- N/A
- Interventions
- Barium (Drug); Diatrizoate (Drug); Iohexol (Drug)
- Age
- Adult, Older Adult · 18+ yrs
- Sex
- All
- Sponsor
- University of California, San Francisco
- Primary completion
- Jan 2017
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Number of Participants With Non-uniform Bowel Lumen Opacification at CT Imaging |
140; 73; 68 | — |
| PRIMARY Severity of CT Imaging Artifacts Caused by the Oral Contrast Agent |
296; 294; 296; 4; 6; 4 | — |
| SECONDARY Extent of Bowel Opacification of Bowel at CT Imaging |
0; 0; 0; 2; 0; 0 | — |
Summary
Although positive oral contrast agents are used for the majority of abdominopelvic CT scans in the United States, the quality of bowel opacification has not been compared between the three major classes of positive oral contrast material (barium sulfate, ionic iodinated contrast material, and non-ionic iodinate contrast material). This is a retrospective single institution study of clinical records to show whether the uniformity of bowel opacification is different between the three main types of positive CT oral contrast material used in the United States (Barium sulfate, Diatrizoate, and Iohexol). The investigators will retrospectively identify 250 patients each who received oral barium sulfate, diatrizoate, and iohexol for CT scanning of the abdomen and pelvis (total 750 patients) and assess the quality of bowel lumen opacification by the positive oral contrast agents.
Eligibility Criteria
Inclusion Criteria
- CT scans in which oral contrast material was given
Exclusion Criteria
- CT scans in which an obvious paucity of oral contrast material is seen,
- CT scans of patients who had studies within 1 week prior where enteric contrast may have been given, including fluoroscopic, endoscopic, or interventional studies
Data sourced from ClinicalTrials.gov (NCT02542046). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.